Loading…

Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior

Rationale Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist. Objectives The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and i...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 2009-03, Vol.202 (4), p.711-718
Main Authors: Bleickardt, C. J., Mullins, D. E., MacSweeney, C. P., Werner, B. J., Pond, A. J., Guzzi, M. F., Martin, F. D. C., Varty, G. B., Hodgson, R. A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303
cites cdi_FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303
container_end_page 718
container_issue 4
container_start_page 711
container_title Psychopharmacology
container_volume 202
creator Bleickardt, C. J.
Mullins, D. E.
MacSweeney, C. P.
Werner, B. J.
Pond, A. J.
Guzzi, M. F.
Martin, F. D. C.
Varty, G. B.
Hodgson, R. A.
description Rationale Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist. Objectives The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and in vivo efficacy in animal models of anxiety-like behavior. Materials and methods The affinity of JNJ-17308616 for the human and rat V1a, V1b, V2, and oxytocin receptors was determined. Central administration of AVP induces a scratching response mediated through the V1a receptor. Inhibition of scratching was used as a behavioral measure of in vivo potency. JNJ-17308616 was tested in five models of anxiety: rat elevated plus-maze (EPM), rat-elevated zero-maze (EZM), rat-conditioned lick suppression (CLS), rat pup separation-induced ultrasonic vocalizations (USV), and mouse marble burying (MMB). Results High affinity for the human V1a receptor ( K i 5.0 nM) was confirmed. However, the rat V1a receptor affinity was more modest ( K i 216 nM), and the compound was not selective over the rat V2 receptor ( K i 276 nM). At 100 mg/kg, JNJ-17308616 significantly reduced anxiety-like behavior in EPM, USV, and MMB; at 30 mg/kg, it was effective in EZM and CLS. JNJ-17308616 neither impaired social recognition nor reduced locomotor activity. Conclusions These results demonstrate the potential for V1a receptor antagonists as novel anxiolytics. Tool compounds that have greater V1a receptor selectivity than JNJ-17308616 are necessary to make precise conclusions about the role of the V1a receptor in affective disorders.
doi_str_mv 10.1007/s00213-008-1354-x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66907543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66907543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303</originalsourceid><addsrcrecordid>eNqFkUuLFDEURoMoTjv6A9xIcOFqojePSqWW0vgaBt2o25DKYzpjdTImaenx15umGwYEMZu7yPm-cHMQek7hNQUY31QARjkBUITyQZD9A7SigjPCYGQP0QqAc8LpoM7Qk1pvoB-hxGN0RtXEuGKwQnq9McXY5kv8bVrMCeeA28bj79Rgk5q5zinWdoEvP18SOnJQksoLHBMu2fnU8LaPpR5SJu2jb3dkiT88nv3G_Iq5PEWPglmqf3aa5-jb-3df1x_J1ZcPn9Zvr4gVUjbiggXvgppHS52fzCCdDWaegzIi-BnczNxIJz5RY4AF3rfls7TeiWDFxIGfo1fH3tuSf-58bXobq_XLYpLPu6qlnGDsof-CDAY6DVx08OVf4E3eldSX0Kz_n4RR0Q7RI2RLrrX4oG9L3JpypynogyN9dKS7I31wpPc98-JUvJu33t0nTlI6wI5A7Vfp2pf7l__d-gcayZvM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218960781</pqid></control><display><type>article</type><title>Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior</title><source>Springer Nature</source><source>SPORTDiscus with Full Text (EBSCOhost)</source><creator>Bleickardt, C. J. ; Mullins, D. E. ; MacSweeney, C. P. ; Werner, B. J. ; Pond, A. J. ; Guzzi, M. F. ; Martin, F. D. C. ; Varty, G. B. ; Hodgson, R. A.</creator><creatorcontrib>Bleickardt, C. J. ; Mullins, D. E. ; MacSweeney, C. P. ; Werner, B. J. ; Pond, A. J. ; Guzzi, M. F. ; Martin, F. D. C. ; Varty, G. B. ; Hodgson, R. A.</creatorcontrib><description>Rationale Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist. Objectives The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and in vivo efficacy in animal models of anxiety-like behavior. Materials and methods The affinity of JNJ-17308616 for the human and rat V1a, V1b, V2, and oxytocin receptors was determined. Central administration of AVP induces a scratching response mediated through the V1a receptor. Inhibition of scratching was used as a behavioral measure of in vivo potency. JNJ-17308616 was tested in five models of anxiety: rat elevated plus-maze (EPM), rat-elevated zero-maze (EZM), rat-conditioned lick suppression (CLS), rat pup separation-induced ultrasonic vocalizations (USV), and mouse marble burying (MMB). Results High affinity for the human V1a receptor ( K i 5.0 nM) was confirmed. However, the rat V1a receptor affinity was more modest ( K i 216 nM), and the compound was not selective over the rat V2 receptor ( K i 276 nM). At 100 mg/kg, JNJ-17308616 significantly reduced anxiety-like behavior in EPM, USV, and MMB; at 30 mg/kg, it was effective in EZM and CLS. JNJ-17308616 neither impaired social recognition nor reduced locomotor activity. Conclusions These results demonstrate the potential for V1a receptor antagonists as novel anxiolytics. Tool compounds that have greater V1a receptor selectivity than JNJ-17308616 are necessary to make precise conclusions about the role of the V1a receptor in affective disorders.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-008-1354-x</identifier><identifier>PMID: 18923820</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Animal behavior ; Animals ; Antagonist drugs ; Anti-Anxiety Agents - pharmacology ; Antidiuretic Hormone Receptor Antagonists ; Anxiety ; Anxiety - psychology ; Arginine Vasopressin - pharmacology ; Behavior, Animal - drug effects ; Biomedical and Life Sciences ; Biomedicine ; Conditioning, Operant - drug effects ; Dose-Response Relationship, Drug ; Female ; Hormones ; Male ; Mice ; Mice, Knockout ; Motor Activity - drug effects ; Neurosciences ; Original Investigation ; Ovariectomy ; Pharmacology/Toxicology ; Psychiatry ; Psychopharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Vasopressin - genetics ; Recognition (Psychology) - drug effects ; Rodents ; Social Behavior ; Spiro Compounds - pharmacology ; Vasopressins - metabolism ; Vocalization, Animal - drug effects</subject><ispartof>Psychopharmacology, 2009-03, Vol.202 (4), p.711-718</ispartof><rights>Springer-Verlag 2008</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303</citedby><cites>FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18923820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bleickardt, C. J.</creatorcontrib><creatorcontrib>Mullins, D. E.</creatorcontrib><creatorcontrib>MacSweeney, C. P.</creatorcontrib><creatorcontrib>Werner, B. J.</creatorcontrib><creatorcontrib>Pond, A. J.</creatorcontrib><creatorcontrib>Guzzi, M. F.</creatorcontrib><creatorcontrib>Martin, F. D. C.</creatorcontrib><creatorcontrib>Varty, G. B.</creatorcontrib><creatorcontrib>Hodgson, R. A.</creatorcontrib><title>Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><addtitle>Psychopharmacology (Berl)</addtitle><description>Rationale Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist. Objectives The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and in vivo efficacy in animal models of anxiety-like behavior. Materials and methods The affinity of JNJ-17308616 for the human and rat V1a, V1b, V2, and oxytocin receptors was determined. Central administration of AVP induces a scratching response mediated through the V1a receptor. Inhibition of scratching was used as a behavioral measure of in vivo potency. JNJ-17308616 was tested in five models of anxiety: rat elevated plus-maze (EPM), rat-elevated zero-maze (EZM), rat-conditioned lick suppression (CLS), rat pup separation-induced ultrasonic vocalizations (USV), and mouse marble burying (MMB). Results High affinity for the human V1a receptor ( K i 5.0 nM) was confirmed. However, the rat V1a receptor affinity was more modest ( K i 216 nM), and the compound was not selective over the rat V2 receptor ( K i 276 nM). At 100 mg/kg, JNJ-17308616 significantly reduced anxiety-like behavior in EPM, USV, and MMB; at 30 mg/kg, it was effective in EZM and CLS. JNJ-17308616 neither impaired social recognition nor reduced locomotor activity. Conclusions These results demonstrate the potential for V1a receptor antagonists as novel anxiolytics. Tool compounds that have greater V1a receptor selectivity than JNJ-17308616 are necessary to make precise conclusions about the role of the V1a receptor in affective disorders.</description><subject>Animal behavior</subject><subject>Animals</subject><subject>Antagonist drugs</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Antidiuretic Hormone Receptor Antagonists</subject><subject>Anxiety</subject><subject>Anxiety - psychology</subject><subject>Arginine Vasopressin - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Conditioning, Operant - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hormones</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Motor Activity - drug effects</subject><subject>Neurosciences</subject><subject>Original Investigation</subject><subject>Ovariectomy</subject><subject>Pharmacology/Toxicology</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Vasopressin - genetics</subject><subject>Recognition (Psychology) - drug effects</subject><subject>Rodents</subject><subject>Social Behavior</subject><subject>Spiro Compounds - pharmacology</subject><subject>Vasopressins - metabolism</subject><subject>Vocalization, Animal - drug effects</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkUuLFDEURoMoTjv6A9xIcOFqojePSqWW0vgaBt2o25DKYzpjdTImaenx15umGwYEMZu7yPm-cHMQek7hNQUY31QARjkBUITyQZD9A7SigjPCYGQP0QqAc8LpoM7Qk1pvoB-hxGN0RtXEuGKwQnq9McXY5kv8bVrMCeeA28bj79Rgk5q5zinWdoEvP18SOnJQksoLHBMu2fnU8LaPpR5SJu2jb3dkiT88nv3G_Iq5PEWPglmqf3aa5-jb-3df1x_J1ZcPn9Zvr4gVUjbiggXvgppHS52fzCCdDWaegzIi-BnczNxIJz5RY4AF3rfls7TeiWDFxIGfo1fH3tuSf-58bXobq_XLYpLPu6qlnGDsof-CDAY6DVx08OVf4E3eldSX0Kz_n4RR0Q7RI2RLrrX4oG9L3JpypynogyN9dKS7I31wpPc98-JUvJu33t0nTlI6wI5A7Vfp2pf7l__d-gcayZvM</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Bleickardt, C. J.</creator><creator>Mullins, D. E.</creator><creator>MacSweeney, C. P.</creator><creator>Werner, B. J.</creator><creator>Pond, A. J.</creator><creator>Guzzi, M. F.</creator><creator>Martin, F. D. C.</creator><creator>Varty, G. B.</creator><creator>Hodgson, R. A.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior</title><author>Bleickardt, C. J. ; Mullins, D. E. ; MacSweeney, C. P. ; Werner, B. J. ; Pond, A. J. ; Guzzi, M. F. ; Martin, F. D. C. ; Varty, G. B. ; Hodgson, R. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animal behavior</topic><topic>Animals</topic><topic>Antagonist drugs</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Antidiuretic Hormone Receptor Antagonists</topic><topic>Anxiety</topic><topic>Anxiety - psychology</topic><topic>Arginine Vasopressin - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Conditioning, Operant - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hormones</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Motor Activity - drug effects</topic><topic>Neurosciences</topic><topic>Original Investigation</topic><topic>Ovariectomy</topic><topic>Pharmacology/Toxicology</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Vasopressin - genetics</topic><topic>Recognition (Psychology) - drug effects</topic><topic>Rodents</topic><topic>Social Behavior</topic><topic>Spiro Compounds - pharmacology</topic><topic>Vasopressins - metabolism</topic><topic>Vocalization, Animal - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bleickardt, C. J.</creatorcontrib><creatorcontrib>Mullins, D. E.</creatorcontrib><creatorcontrib>MacSweeney, C. P.</creatorcontrib><creatorcontrib>Werner, B. J.</creatorcontrib><creatorcontrib>Pond, A. J.</creatorcontrib><creatorcontrib>Guzzi, M. F.</creatorcontrib><creatorcontrib>Martin, F. D. C.</creatorcontrib><creatorcontrib>Varty, G. B.</creatorcontrib><creatorcontrib>Hodgson, R. A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Psychology Journals</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bleickardt, C. J.</au><au>Mullins, D. E.</au><au>MacSweeney, C. P.</au><au>Werner, B. J.</au><au>Pond, A. J.</au><au>Guzzi, M. F.</au><au>Martin, F. D. C.</au><au>Varty, G. B.</au><au>Hodgson, R. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><addtitle>Psychopharmacology (Berl)</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>202</volume><issue>4</issue><spage>711</spage><epage>718</epage><pages>711-718</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist. Objectives The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and in vivo efficacy in animal models of anxiety-like behavior. Materials and methods The affinity of JNJ-17308616 for the human and rat V1a, V1b, V2, and oxytocin receptors was determined. Central administration of AVP induces a scratching response mediated through the V1a receptor. Inhibition of scratching was used as a behavioral measure of in vivo potency. JNJ-17308616 was tested in five models of anxiety: rat elevated plus-maze (EPM), rat-elevated zero-maze (EZM), rat-conditioned lick suppression (CLS), rat pup separation-induced ultrasonic vocalizations (USV), and mouse marble burying (MMB). Results High affinity for the human V1a receptor ( K i 5.0 nM) was confirmed. However, the rat V1a receptor affinity was more modest ( K i 216 nM), and the compound was not selective over the rat V2 receptor ( K i 276 nM). At 100 mg/kg, JNJ-17308616 significantly reduced anxiety-like behavior in EPM, USV, and MMB; at 30 mg/kg, it was effective in EZM and CLS. JNJ-17308616 neither impaired social recognition nor reduced locomotor activity. Conclusions These results demonstrate the potential for V1a receptor antagonists as novel anxiolytics. Tool compounds that have greater V1a receptor selectivity than JNJ-17308616 are necessary to make precise conclusions about the role of the V1a receptor in affective disorders.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>18923820</pmid><doi>10.1007/s00213-008-1354-x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0033-3158
ispartof Psychopharmacology, 2009-03, Vol.202 (4), p.711-718
issn 0033-3158
1432-2072
language eng
recordid cdi_proquest_miscellaneous_66907543
source Springer Nature; SPORTDiscus with Full Text (EBSCOhost)
subjects Animal behavior
Animals
Antagonist drugs
Anti-Anxiety Agents - pharmacology
Antidiuretic Hormone Receptor Antagonists
Anxiety
Anxiety - psychology
Arginine Vasopressin - pharmacology
Behavior, Animal - drug effects
Biomedical and Life Sciences
Biomedicine
Conditioning, Operant - drug effects
Dose-Response Relationship, Drug
Female
Hormones
Male
Mice
Mice, Knockout
Motor Activity - drug effects
Neurosciences
Original Investigation
Ovariectomy
Pharmacology/Toxicology
Psychiatry
Psychopharmacology
Rats
Rats, Sprague-Dawley
Receptors, Vasopressin - genetics
Recognition (Psychology) - drug effects
Rodents
Social Behavior
Spiro Compounds - pharmacology
Vasopressins - metabolism
Vocalization, Animal - drug effects
title Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A19%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20V1a%20antagonist,%20JNJ-17308616,%20in%20rodent%20models%20of%20anxiety-like%20behavior&rft.jtitle=Psychopharmacology&rft.au=Bleickardt,%20C.%20J.&rft.date=2009-03-01&rft.volume=202&rft.issue=4&rft.spage=711&rft.epage=718&rft.pages=711-718&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-008-1354-x&rft_dat=%3Cproquest_cross%3E66907543%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c466t-dfc0edf8b7c1de9a56dcfabbf8a4feb0db2d719391aa02f33543b6ced4fc49303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218960781&rft_id=info:pmid/18923820&rfr_iscdi=true